Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 9665 - 9672 of 12086 results

Privacy Monday - March 23, 2015: COPPA Refresh
March 23, 2015| Blog| Viewpoint

More “Broken Windows”: SEC Charges Schedule 13D Filers with Disclosure Violations for Failing to Update Ownership Reports
March 23, 2015| Blog| Viewpoint

Upcoming Webinar: Responding to Insider Data Theft and Disclosure – March 25
March 20, 2015| Blog| Viewpoint

District Court Rules Against Amgen's Motion for Preliminary Injunction to Prevent Marketing of Sandoz's Biosimilar Zarxio
March 20, 2015| Blog| Viewpoint

Proposed Replacement of Sustainable Growth Rate Addresses Telehealth
March 20, 2015| Blog| Viewpoint

Precedent and the Price Explain Why Target and the Consumer Class Agreed to an Early Data Breach Settlement
March 20, 2015| Blog| Viewpoint

Round of 32: Social Media Policies over At-Will Employment
March 20, 2015| Blog| Viewpoint

Delaware Legislature Introduces Rapid Arbitration Act
March 20, 2015| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
